BOTHELL, WA--(Marketwire - December 03, 2008) - MDRNA, Inc. (NASDAQ: MRNA) announced today positive in vivo efficacy data on its proprietary Unlocked Nucleic Acid (UNA) siRNAs in animal models, demonstrating up to 90% knockdown of ApoB. In addition, the Company continues to report effective and safe delivery of its Lead Candidate for hypercholesterolemia in animal models, with no increase in blood markers of liver or kidney toxicity in single and repeat dosing studies up to 9 mg/kg. The data were presented by Michael V. Templin, Ph.D., Vice President, Discovery Research and Pharmaceutical Development of MDRNA, at the Informa Life Sciences 9th Annual Conference, EuroTIDES, in Düsseldorf, Germany.
